Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03358472
Title Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Incyte Corporation

head and neck squamous cell carcinoma



Carboplatin + Fluorouracil

Epacadostat + Pembrolizumab

Cetuximab + Cisplatin

Age Groups: adult | senior
Covered Countries USA | ITA | ESP | CAN | AUT

No variant requirements are available.